BlackBird Financial LP Announces Strategic Investment in Lululemon, Emphasizing Brand Leadership and Attractive Valuation

Toms River, NJ, 19th August 2025, ZEX PR WIRE, BlackBird Financial LP, led by Judah Spinner, CFA, is pleased to  announce its recent investment in Lululemon Athletica (NASDAQ: LULU). The firm’s  investment highlights its view that Lululemon’s market leadership and brand strength are paired  with what they see as an attractive and undervalued entry point, offering a compelling  opportunity to invest in a truly exceptional company. 

“Lululemon is a standout in the retail world,” said Judah Spinner, Founder and Chief Investment  Officer of BlackBird Financial LP. “They have built an incredibly strong brand name and are the  clear leader in their category. What’s more, their sales per square foot are among the highest in  the industry. Because of the industry’s recent slowdown, many investors have turned more  pessimistic, allowing us to purchase Lululemon at what we believe is a very favorable  valuation.” 

Competitive and Market Leadership 

Lululemon has carved out a dominant position in the athleisure and activewear market. The  company’s brand recognition is second to none, and its retail operations consistently deliver  exceptional sales per square foot. Lululemon’s growth in China has been particularly impressive,  and the brand has successfully expanded its presence in Europe as well. Moreover, while  menswear currently represents a smaller portion of overall sales, it is growing rapidly and  represents a significant growth avenue for the future. 

Company Background and Leadership 

Lululemon was founded in 1998 by Chip Wilson in Vancouver, Canada. Originally established  as a design studio by day and a yoga studio by night, the company quickly evolved into a leading  global brand in the athleisure market. Over the years, Lululemon has become synonymous with  high-quality activewear and a loyal customer base that spans the globe. 

Since 2018, the company has been led by CEO Calvin McDonald. McDonald brought a wealth  of retail experience to Lululemon and has been instrumental in guiding the company through a  period of robust growth and international expansion. Under his leadership, Lululemon has not  only strengthened its core product lines but also expanded into new categories and markets. 

“We have immense confidence in Calvin McDonald and his vision for Lululemon’s future,” Spinner noted. “He has articulated a clear strategy focused on innovation, customer experience,  and international growth. We believe in the direction he’s taking the company and are excited to  support Lululemon as it continues to thrive.” 

Financial Performance and Capital Discipline 

Lululemon has demonstrated strong financial management. While the company made a notable  misstep with its 2020 acquisition of Mirror, a home-fitness startup purchased for $500 million, 

the outcome of that deal did not meet expectations. By the end of fiscal year 2022, Lululemon  recorded a post-tax impairment charge of approximately $442.7 million, effectively writing off  most of the acquisition and eventually shutting down its operations. 

Nevertheless, Lululemon has otherwise been disciplined in capital allocation. Over the past three  years, the company has repurchased a total of roughly 6.6 million shares, spending  approximately $1.9 billion on buybacks. This has reduced the share count significantly,  enhancing shareholder value and demonstrating the company’s commitment to returning capital  to investors. In fiscal year 2024, Lululemon reported net revenue of $10.6 billion, a 10% increase  from the previous year, while net income grew by 17% to $1.8 billion, both record highs for the  company. 

Strategic Growth and Future Potential 

Looking ahead, BlackBird sees significant growth potential for Lululemon, not only in its  established markets but also through continued expansion in Europe and further penetration of  the men’s segment. The company’s ability to innovate and outperform competitors sets it apart.  Management has focused on maintaining strong cash flows, and despite the disastrous Mirror  acquisition, they have continued to execute well on their long-term strategy. 

“We think Lululemon’s future remains very bright,” Spinner concluded. “They make excellent  products, have a loyal customer base, and are well-positioned to grow in multiple regions. We’re  confident in their leadership and excited to be long-term partners as they continue to execute.” 

About BlackBird Financial LP 

BlackBird Financial LP, founded by Judah Spinner, is a value-oriented investment firm that  adheres to the Graham-and-Dodd school of investing. They focus on identifying structurally  advantaged businesses and purchasing them at prices well below their intrinsic value.  

In the first half of 2025, BlackBird delivered a net return of 34.4%, significantly outpacing the  S&P 500’s 6.1% return. This performance underscores their commitment to disciplined value  investing and their ability to find opportunity where others overlook it.

To learn more visit: https://blackbirdfinancial.com/

The Doctor’s Choice for Tailored Anaesthetics: Unveiling My Compounding Pharmacy of Roselands Australia

Brisbane, Australia, 19th August 2025, ZEX PR WIRE, Innovation in healthcare often arises from a simple yet profound need, to cater to differences in individual care. For Australians seeking personalized solutions in anaesthetics, My Compounding Pharmacy has emerged as a trusted partner for both patients and doctors alike. With a unique blend of science, artistry, and a deeply rooted commitment to patient well-being, this pharmacy has transformed the way anaesthetic medications are developed and delivered.

Why Personalization Matters in Anaesthetics 

The practice of administering anaesthesia is rarely one-size-fits-all, and for good reason. The nuances of each procedure, patient sensitivity, and even the duration of treatment demand precision and personalization. This is where compounded anaesthetic medications step in to fill the gap left by standardized solutions. 

Patients undergoing tattoo removal, laser rejuvenation, or skin needling, for instance, might experience differing levels of sensitivity or require varying levels of numbing. Compounded anaesthetics provide the flexibility to modify both strengths and compositions, adjusting for specific patient needs with pinpoint accuracy. My Compounding Pharmacy has positioned itself as an authority in this specialized area, offering tailored formulations for a wide variety of procedures. 

The Art and Science of Compounded Anaesthetics 

Unlike mass-manufactured medicines, compounded anaesthetics are developed with the individual at the center. These formulations balance medical science with creative problem-solving, yielding solutions that are as unique as the patients who use them. 

For example, patients or doctors can work closely with the pharmacy to design anaesthetics with concentrations as high as 30% for more complex procedures or consult with pharmacists to create milder formulations without the need for a prescription. This flexibility removes barriers, offering comfortable, accessible solutions tailored to each unique situation. 

Furthermore, the inclusion of agents like epinephrine in formulations adds another layer of customization, allowing doctors to enhance the procedure by minimizing bleeding and prolonging the numbing effect. These adaptations not only improve comfort but also optimize procedural efficacy. 

A Commitment to Excellence 

What truly sets My Compounding Pharmacy apart is its dedication to maintaining the highest standards of quality and safety. Every formulation adheres to stringent regulatory guidelines established by the Pharmacy Board of Australia and the Therapeutic Goods Administration (TGA). This ensures that each compound surpasses safety benchmarks while delivering effective and reliable results for patients. 

The pharmacy’s team, boasting over 85 years of combined experience, brings unparalleled expertise to the table. Their meticulous approach to testing and quality control offers peace of mind to both doctors and patients. Every ingredient used is carefully selected and rigorously checked for efficacy, ensuring that the final product is nothing short of exceptional. 

Bridging the Gap for Doctors and Patients 

Healthcare professionals, especially those in fields like dermatology, dentistry, and cosmetic treatments, often face challenges that standardized medications can’t solve. From complex cases to patients with unique sensitivities, the need for precise solutions is growing. 

My Compounding Pharmacy has stepped in as an invaluable partner to practitioners across Australia. By collaborating with specialists, they enable doctors to provide tailored treatments that improve patient experiences and outcomes. Whether it’s creating allergen-free formulations or suggesting alternatives to discontinued medications, their work empowers clinicians to deliver care without compromising on quality. 

For patients, the pharmacy’s approach transforms what can often be an intimidating process into one that prioritizes comfort and clarity. With options for both prescription and non-prescription anaesthetic solutions, they ensure that no individual is left without the support they need. 

Redefining Patient-Centered Care 

The heart of My Compounding Pharmacy’s mission lies in creating a seamless and supportive experience for their patients. They’ve redefined accessibility, offering online consultations and free 3-minute calls with pharmacists for those who need guidance but lack a prescription. By adapting to patients’ lifestyles and needs, they’ve made advanced healthcare solutions feel tangible and close at hand. 

This personalized approach is why the pharmacy has accrued over 100 five-star reviews, with countless testimonials lauding their responsiveness, expertise, and ability to provide unmatched care. But beyond accolades, it’s their human-centered philosophy that makes them a standout choice for anaesthetic medications in Australia. 

The Future of Compounded Anaesthetics 

The demand for tailored medications will only grow as healthcare continues to evolve. With advancements in both medical technology and patient expectations, compounding pharmacies like My Compounding Pharmacy will remain crucial in bridging the gap between standardized care and personalized medicine. 

For doctors, the pharmacy offers innovative solutions to challenging cases, enabling them to offer more precise and impactful treatment plans. For patients, it provides an opportunity to approach procedures free from the fear of discomfort, knowing their unique needs will be addressed with care and expertise. 

Start Your Journey to Comfort 

Whether you’re preparing for a cosmetic procedure or a medical treatment, the right anaesthetic can transform your experience. My Compounding Pharmacy is here to ensure that your path to comfort begins with high-quality, customized solutions tailored specifically to your needs. 

If you’re a doctor looking for a trusted partner or a patient seeking expert guidance, connect with My Compounding Pharmacy today. Discover the difference that personalized anaesthetic medications can make in your healthcare journey. 

To learn more visit: https://mycompounding.com.au/

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

 

Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.

The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.

According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.

“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum

At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.

To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.

Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.

Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.

CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.

 

Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth

According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.

Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.

In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.

Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

Crown Point Capital Releases Mid-Year Performance Overview Reinforcing Investor Confidence

Crown Point Capital has released its mid-year performance overview for 2025, highlighting steady growth, robust client engagement, and a strengthened market position. The report reflects the company’s ongoing ability to deliver consistent results across varying market conditions, reinforcing confidence among its expanding global investor base.

Strong Performance in a Volatile Market

The first half of 2025 has been marked by uncertainty across global financial markets. Digital assets in particular have experienced significant volatility, testing the resilience of platforms and investors alike. Despite these conditions, Crown Point Capital has demonstrated stability, maintaining steady growth and reinforcing its position as a secure trading platform for clients worldwide.

The firm’s strategies have been focused on balancing innovation with responsibility, ensuring that investor portfolios are supported with effective risk management frameworks. This approach has been recognized in Crown Point Capital reviews, where clients frequently note the platform’s ability to remain reliable even during turbulent market cycles.

Delivering Consistency for Clients

Crown Point Capital’s mid-year results confirm that consistency remains a defining feature of its operations. By prioritizing stability alongside growth, the company has delivered results that underscore its long-term focus on client success.

The performance overview also reflects the impact of the firm’s investments in technology and infrastructure. These enhancements have supported trading efficiency, safeguarded client assets, and improved overall platform reliability. Positive sentiment in Crown Point Capital reviews often highlights these qualities as key reasons for investor confidence in the company.

Expanding Global Reach

A significant theme in the mid-year report is Crown Point Capital’s expanding global reach. The company has broadened access to its platform across multiple regions, responding to growing international demand for digital asset trading solutions.

This global expansion has been supported by scalable infrastructure and adaptive strategies, ensuring the platform can meet the needs of both retail and institutional clients. The breadth of this reach has contributed to the company’s reputation as a forward-looking trading platform, a reputation frequently reflected in Crown Point Capital reviews.

Focus on Investor Protection

The mid-year overview also highlighted Crown Point Capital’s continued emphasis on investor protection. In an industry where transparency and security are increasingly valued, the company has reinforced its protective measures, introduced additional oversight processes, and strengthened reporting standards.

These initiatives are designed to provide investors with clarity and confidence, particularly during periods of market uncertainty. By embedding protection into every stage of its operations, Crown Point Capital is ensuring that growth opportunities are balanced with safeguards. This balance is frequently cited in Crown Point Capital reviews, where clients describe the firm as both innovative and dependable.

Strategic Adaptability

Adaptability has been another defining feature of Crown Point Capital’s performance in 2025. The company has demonstrated its ability to respond quickly to shifting market conditions, adjusting its strategies to ensure both resilience and opportunity.

This flexibility has been crucial in delivering positive outcomes despite unpredictable market movements. By refining its approach in real time, the firm has shown that it can remain competitive while protecting client interests. Such adaptability continues to strengthen investor confidence, a sentiment often echoed in Crown Point Capital reviews.

Building for the Future

Looking ahead, Crown Point Capital has indicated that it will continue to build on the progress achieved during the first half of the year. The company’s roadmap includes further enhancements to its trading infrastructure, expanded investor support programs, and additional initiatives aimed at strengthening transparency and long-term trust.

By maintaining a focus on innovation, accountability, and client protection, Crown Point Capital is positioning itself to sustain growth through the remainder of 2025 and beyond. The mid-year performance overview demonstrates not only past achievements but also a clear vision for the future, aligning the company with the expectations of global investors.

Conclusion

The release of Crown Point Capital’s mid-year performance overview underscores the company’s resilience, adaptability, and commitment to clients in an evolving market. By delivering consistent results, reinforcing transparency, and expanding global access, the firm continues to strengthen investor confidence and set a benchmark for responsible trading platforms.

As the financial landscape continues to change, Crown Point Capital remains focused on its mission to combine innovation with security, providing investors with a reliable foundation for long-term growth.

Media Contact

Organization: Crown Point Capital

Contact Person: david adler

Website: https://www.crownpoint-capital.com

Email: Send Email

Address:10 St. Petersrasse

City: Zurich

State: Zurich

Country:Switzerland

Release id:32584

The post Crown Point Capital Releases Mid-Year Performance Overview Reinforcing Investor Confidence appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Meet the Characters of Syrenya The Naked Queen in Stunning New Book Trailer

Alan R. Hall’s second book trailer introduces the unforgettable characters of ‘Syrenya: The Naked Queen,’ combining medieval fantasy with emotional depth.

A new chapter in the world of medieval fantasy unfolds as the second video book trailer for ‘Syrenya: The Naked Queen’ by Alan R. Hall makes its global debut. This visually striking trailer dives into the heart of the narrative, introducing readers to the key characters who shape the emotional and political landscape of Tabithia—a kingdom caught in the tension of love, power, and rebellion.

Set in AD 1147, when a youthful King Arthur is still forming visions of Camelot, the story begins with an unexpected visitor to Arthur’s court. Darien, a mysterious young man, arrives with a tale that disrupts everything the king thinks he knows. He speaks of his mother, Syrenya—the Naked Queen of Tabithia—whose story of courage, sacrifice, and sensual strength challenges both historical truth and Arthur’s perception of destiny.

The second trailer brings Syrenya to life as a commanding figure: fearless, vulnerable, and defiant against a king’s cruelty. Viewers also meet Alisa, whose quiet strength reveals the cost of dissent, and Ariadne, whose fiery passion threatens to reshape the kingdom. King Ballizar is portrayed as a ruler divided by lust and legacy, while Darien emerges as the bridge between past and future—bearing the weight of secrets that could change the world.

This trailer mirrors the tone and intensity of the book, drawing readers deeper into the mystery of Syrenya’s identity and the forces driving the rebellion in Tabithia. 

Author Alan R. Hall writes a vivid tale that combines epic storytelling with character-driven drama. With elements of Arthurian legend, political intrigue, and personal awakening, ‘Syrenya: The Naked Queen’ continues to gain attention among fans of historical fantasy and mature epic fiction.

The second video trailer is now available to view online. For readers seeking a compelling saga of myth, identity, and transformation, this immersive glimpse into ‘Syrenya: The Naked Queen’ is not to be missed.

To purchase, please click here: https://rb.gy/2mnga2

Watch the trailer now and step into the world of Syrenya—where history meets legend, and courage defines a queen.

About Explora Books: 

Explora Books is a book marketing firm located in the heart of Vancouver, British Columbia, Canada. The company specializes in self-publishing and marketing, taking pride in its exhaustive research and creative strategies that provide wider avenues for aspiring authors to gain recognition for their works. Explora Books aims to guide authors through the complexities of self-publishing, offering convenient solutions to navigate this process. The firm fosters and redefines creativity and innovation, setting new industry standards. Explora Books is dedicated to empowering authors globally.

Media Contact

Organization: Explora Books Ltd

Contact Person: Simon Pratt

Website: https://explorabooks.com/home

Email:
spratt@explorabooks.com

Contact Number: +16043306795

Address:Jameson Offices, 838 W Hastings St w, Vancouver, BC V6C 0A6, Canada

City: Vancouver

State: British Columbia

Country:Canada

Release id:32575

The post Meet the Characters of Syrenya The Naked Queen in Stunning New Book Trailer appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

TSS HVAC Services Celebrates 40 Years Cementing Reputation as Best Commercial HVAC Contractor in Boise

TSS HVAC Services, an established name in commercial HVAC solutions, proudly celebrates its milestone of 40 years in business. Serving clients across the Pacific Northwest – including Idaho, Oregon, and Washington – TSS HVAC Services works with commercial property managers, facility managers, building owners, and national HVAC service companies to deliver expert installations, repairs, and ongoing maintenance for buildings ranging from 3,000 to 500,000 square feet.

Since 1985, TSS HVAC Services has built a reputation for efficient, responsive service and honest communication – qualities that have earned the loyalty of property management companies, national brands, and building owners who trust TSS to keep their facilities running smoothly.

“We build lasting relationships with property managers, giving them a trusted partner for all their HVAC needs,” said Steve Miller, President of TSS HVAC Services & TSS Home Comfort. “We pride ourselves on our ability to handle any system, make, or model, and to provide solutions tailored to each client’s unique needs.”

TSS HVAC Services employs NATE-certified technicians and is accredited by the Better Business Bureau (BBB). The company is also a member of the Idaho Associated General Contractors (AGC) and BOMA International. Staying at the forefront of HVAC technology allows TSS to meet the demands of a wide range of systems and provide long-term value for its clients.

Comprehensive Commercial HVAC Solutions

TSS HVAC Services offers a complete spectrum of services, including:

  • Commercial HVAC Installations – Turnkey solutions for new construction or system upgrades
  • Repairs & Emergency Service – Quick, reliable fixes to minimize downtime
  • Preventive Maintenance Programs – Extending system life and improving efficiency
  • System Diagnostics & Performance Audits – Ensuring optimal operation year-round
  • Multi-Site & National Account Support – Service for regional and national clients

The company’s Straight-Talk Policy ensures clients always know the true condition of their HVAC systems, the costs of repairs or installations, and the best path forward for efficiency and comfort.

Contact TSS HVAC Services

To learn more about TSS HVAC Services or to request a consultation, call (208) 376-1393 or visit https://www.tsshvac.com.

TSS HVAC Services
1712 S Roosevelt St, Boise, ID
Phone: (208) 376-1393

About TSS HVAC Services

TSS HVAC Services specializes in commercial HVAC installation, repair, and maintenance for facilities across the Pacific Northwest including Idaho, Oregon, and Washington. With NATE-certified technicians, BBB accreditation, and 40 years of experience, TSS HVAC Services provides tailored solutions for property managers, facility managers, and national accounts, delivering reliable comfort and efficiency year-round.

Media Contact

Organization: TSS HVAC Services

Contact Person: Natalie Martin

Website: https://www.tsshvac.com/

Email: Send Email

Contact Number: +12083761393

Address:1712 S Roosevelt St

City: Boise

State: ID

Country:United States

Release id:26036

The post TSS HVAC Services Celebrates 40 Years Cementing Reputation as Best Commercial HVAC Contractor in Boise appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Incoin Trading Center Introduces Mental Wellness Support Module for Traders

Incoin Trading Center launches a behavioral health support module aimed at improving emotional resilience and mental clarity in high-stakes trading environments.

Incoin Trading Center today announced the rollout of its new Mental Wellness Support Module, an integrated platform feature designed to help traders manage emotional stress, impulsive behaviors, and burnout associated with fast-paced financial decision-making.

The module combines real-time mood analytics, AI-assisted stress indicators, and customized cognitive training exercises. It seeks to foster healthier trading habits by helping users recognize early signs of anxiety, decision fatigue, or emotional trading cycles.

“Trading isn’t just numbers and strategy—it’s also about psychology,” said Alyssa Tan, Chief Operating Officer of Incoin Trading Center. “By integrating emotional awareness tools into the trading journey, we’re reinforcing our belief that successful investing requires both mental focus and emotional balance.”

Key Features of the Module:

Real-Time Sentiment Tracking: Lightweight prompts assess mood and focus levels during active trading hours.

AI-Powered Risk Emotion Alerts: Notifications detect high-stress behaviors (e.g., rapid order changes or pattern reversals).

Personalized Breathing & Focus Routines: In-platform exercises adapted to the user’s behavioral data.

Trade Journal with Emotional Tagging: Users can label trades with emotional context—such as “overconfident,” “hesitant,” or “pressured.”

Weekly Behavioral Reports: Summarized analytics on user mood vs. trading performance, offering insight into psychological triggers.

Privacy and Ethics

All data processed through the wellness module is fully anonymized, stored locally when possible, and never used for predictive modeling of user trades. The initiative is part of Incoin Trading Center’s broader commitment to ethical AI and human-centered fintech innovation.

Future Roadmap

The platform plans to expand the module in 2026 with community-led wellness forums and optional check-ins with certified behavioral finance advisors.

About Incoin Trading Center
Incoin Trading Center is a global fintech platform specializing in AI-powered trading infrastructure, behavioral data integration, and user-centric service innovation. Its mission is to provide secure, responsive, and emotionally intelligent tools for modern investors.

Additional Resources:
https://www.incoin.pro

https://www.incoin-trace.com

https://www.incoin-overview.com

https://www.in-coin.net

https://www.incoin-scam.com

 

Media Contact

Organization: Incoin

Contact Person: Paige Monroe

Website: https://lncoin.com/

Email: Send Email

Country:United States

Release id:32581

The post Incoin Trading Center Introduces Mental Wellness Support Module for Traders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Chef Liz Terletskaia to Lead Exclusive 2-Day Master Class at Florida Education Institute

lorida Education Institute in Miami is hosting a 2-day master class on August 26-28, 2025, led by renowned pastry chef Liz Terletskaia. The class will focus on European-style mousse cakes, teaching signature techniques like mirror glaze and flocking. Open to students and the public, participants can earn certification upon passing a final review. Limited spots are available for a personalized experience. For details or registration, contact the institute.

Miami, FL – August 19, 2025 – Florida Education Institute, a leader in Miami’s culinary arts training, is thrilled to announce an exclusive 2-day master class led by renowned pastry chef and educator Liz Terletskaia. With over a decade of experience and more than 40 master classes conducted across the United States, Chef Liz is celebrated for her expertise in pastry arts and her passion for mousse cake creation, mirror glaze, and unique flocking techniques.

The master class, scheduled for August 26-28, 2025, will focus on the art of preparing European-style moussecakes, showcasing Chef Liz’s signature techniques for crafting stunning designs and delectable flavors.Participants will gain hands-on experience, and students who successfully pass the final review will earn certification from Chef Liz.

“We are honored to host Chef Liz Terletskaia. She is a perfect fit for our school, bringing multicultural culinary knowledge and her extraordinary designs,” said Isamar Leal, Chef, MDM, M.Ed., at Florida Education Institute.“This master class offers a unique opportunity for our students to elevate their skills under the guidance of a true industry leader.”

The event is open to both Florida Education Institute students and the public, with limited spots available to ensure a personalized learning experience. For more information or to register, contact Florida EducationInstitute.

About Florida Education Institute

Florida Education Institute is Miami’s premier destination for culinary arts education, offering cutting-edge programs that empower aspiring chefs to excel in the culinary world.

Liz’ Instagram: @Lizzie_Sweezie

 

Media Contact

Organization: Lizzie Sweezie LLC

Contact Person: Liz’ assistant

Website: https://lizterletskaia.com

Email: Send Email

City: Miami

State: Florida

Country:United States

Release id:32570

The post Chef Liz Terletskaia to Lead Exclusive 2-Day Master Class at Florida Education Institute appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Becky Larson Bloom Publishes Debut Novel A Chance Meeting

Becky Larson Bloom, a Colorado-based writer, has released her debut novel, “A Chance Meeting”. This new work blends themes of healing, identity, and resilience into a story that reflects how human connection can transform lives.

 

At the heart of the novel is Ann, a woman who boards a train to Rome carrying the weight of years of emotional struggle. In a moment of chance, she meets Jay, a soldier returning home whose path is marked by sacrifice and uncertainty. What begins as an unexpected encounter unfolds into a bond that challenges them to face their pasts and embrace new beginnings.

The narrative explores their romance and the quiet courage required to trust again after hardship. Through Ann’s perspective, readers experience the tension between vulnerability and strength, and through Jay’s journey, they see the resilience required to heal from life’s unseen wounds. Together, their story reveals how two people, seemingly worlds apart, can help each other move forward with honesty and hope.

The settings of Rome and Colorado play a vital role in the book, serving as more than just backdrops. With its historic streets and timeless atmosphere, Rome becomes a place of renewal and rediscovery for Ann. Colorado, with its open landscapes and sense of calm, reflects her inner search for peace. Bloom’s descriptive writing allows readers to travel with her characters, immersing them in each environment and making every place feel alive.

At 70 years old, Becky Larson Bloom brings a rare and authentic perspective to her debut. Her decision to pursue writing later in life stems from a lifelong love of literature and a desire to capture the complexities of human experience. Bloom has long believed in stories’ ability to provide comfort and inspiration. In “A Chance Meeting”, she draws on her observations of resilience and personal growth to shape genuine and relatable characters.

The novel is more than a romance. It reflects how life often presents second chances when they are least expected. Bloom highlights the importance of self-acceptance, showing how Ann and Jay learn to find strength in vulnerability and meaning in connection. Their journey speaks to readers of all ages, reminding them that the pursuit of happiness and authenticity is never bound by time.

Bloom hopes her debut will encourage readers navigating their transitions, whether through loss, change, or new beginnings. She views storytelling as a way to honor the resilience of the human spirit and believes that literature can serve as a bridge between shared struggles and hope.

This read is now available on major digital platforms, making it accessible to a wide readership. The release marks an important milestone in Bloom’s career as an author, and she is already planning future works that will continue to explore themes of love, growth, and transformation.

Media Contact

Organization: Book Publisher

Contact Person: Becky Larson Bloom

Website: https://www.amazon.com/dp/B0F2J42RKL

Email: Send Email

Contact Number: +12185919328

Country:United States

Release id:31394

The post Becky Larson Bloom Publishes Debut Novel A Chance Meeting appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file